Skip to main content
Log in

Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma

  • Original Articles
  • 5-Fluorouracil, 5-Fluoro-2′-Deoxy-5′-Monophosphate, Tissue Pharmacokinetics, Plasma Pharmacokinetics
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Concentrations of 5-fluorouracil (5-FU) and its active metabolite 5-fluoro-2′-deoxy-5′-monophosphate (FdUMP) were measured in biopsy specimens of tumor tissue, normal mucosa, metastatic liver nodules, and normal liver tissue obtained from 39 patients and in two murine colon tumors (colon 26 and colon 38) after a single injection of 5FU at a therapeutic dose (500 mg/m2 and 100 mg/kg, respectively). These data were compared with plasma concentrations. Peak plasma concentrations (300–500 μm) of 5FU were comparable in human and murine plasma. The half-life of plasma elimination (during the period from 15 to 120 min) in both mouse and man ranged from 10 to 20 min, whereas at between 2 and 8 h, plasma concentrations varied from 0.1 to 1 μm, the half-life being about 100 min. In both species, 5FU could be measured in plasma at concentrations ranging from 0.01 to 1 μm for several days after 5FU treatment. 5FU concentrations in tissue samples obtained from 14 patients were measured during the time range of 1–6 h, those in samples taken from 7 patients, during the interval of 19–27 h; and those in samples obtained from 18 patients, within the interval of 40–48 h after injection. 5FU tumor concentrations varied between 0.78–21.6, 0.44–6.1, and 0.17–10.8 μmol/kg wet wt., respectively. Some of the 48-h samples were obtained from patients who had received leucovorin plus 5FU; coadministration of leucovorin did not alter 5FU tissue concentrations. At between 4 and 48 h, the tissue concentration/plasma concentration ratio was at least 10. 5FU concentrations in murine tumors were measured for up to 10 days after 5FU administration, with plateau 5FU tumor concentrations being about 50 μmol/kg wet wt. in colon 38 and about 200 μmol/kg wet wt. in colon 26 at 2 h after treatment; after 4 days, values of 0.5 and 4.8 μmol/kg, respectively, were obtained and after 10 days, respective concentrations of 0.1 and 0.07 μmol/kg were detected. The FdUMP concentrations measured in colon 26 and colon 38 tumors were 214 and 46 pmol/g, respectively, at 2 h after 5FU administration, and these values subsequently decreased to about 15 pmol/g in both tumors. In human tumors the initial FdUMP concentration ranged from 10 to 1000 pmol/g; at later time points the level of FdUMP was just above the detection limit of the assay. In liver metastases, high 5FU concentrations seemed to be related to high levels of FdUMP, which was likely of importance for the antitumor effect. The prolonged retention of 5FU should be taken into consideration in the design of biochemical modulation studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bates CD, Watson DG, Willmott N, Logan H, Golberg J (1991) The analysis of 5-fluorouracil in human plasma by gas chromatography-negative ion chemical ionization mass spectrometry (GC-NICIMS) with stable isotope dilution. J Pharm Biomed Anal 9: 19–21

    Google Scholar 

  2. Byfield JE (1988) 5-Fluorouracil radiation sensitization—a brief review. Invest New Drugs 7: 111–116

    Google Scholar 

  3. Collins JM (1985) Pharmacokinetics of 5-fluorouracil infusion in the rat: comparison with man and other species. Cancer Chemother Pharmacol 14: 108–111

    Google Scholar 

  4. Danenberg PV (1977) Thymidylate synthetase—a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473: 73–92

    Google Scholar 

  5. De Bruijn EA, Remeyer L, Tjaden UR, Erkelens C, De Brauw LM, Van de Velde CJH (1986) Non-linear pharmacokinetics of 5-fluorouracil. Biochem Pharmacol 35: 2461–2465

    Google Scholar 

  6. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215–237

    Google Scholar 

  7. Domin BA, Mahony WB (1990) 5-Fluorouracil transport into human erythrocytes (abstract 59). Proc Am Assoc Cancer Res 31: 10

    Google Scholar 

  8. Donelli MG, D'Incalci M, Garattini S (1984) Pharmacokinetics studies of anticancer drugs in tumor-bearing animals. Cancer Treat Rep 68: 381–400

    Google Scholar 

  9. Doong SL, Dolnick BJ (1988) 5-Fluorouracil substitution alters pre-mRNA splicing in vitro. J Biol Chem 263: 4467–4473

    Google Scholar 

  10. El Hag IA, Jakobsson B, Christensson PI, Ericksen C, Joensson PE, Stenram U (1987) Modulation of 5-fluorouracil toxicity by uridine, deoxyuridine, orotate and dipyridamole in normal tissues of rats with liver adenocarcinoma. In Vivo 1: 309–312

    Google Scholar 

  11. Finan PJ, Chisholm EM, Woodhouse L, Giles GR (1987) The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer. Eur J Surg Oncol 13: 349–353

    Google Scholar 

  12. Finn C, Sadée W (1975) Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. Cancer Chemother Rep 59: 279–286

    Google Scholar 

  13. Guerquin-Kern JL Leteurtre F, Croisy A, Lloste J-M (1991) pH Dependence of 5-fluorouracil uptake observed by in vivo31P and19F nuclear magnetic resonance spectroscopy. Cancer Res 51: 5770–5773

    Google Scholar 

  14. Hull WE, Port RE, Herrmann R, Britsch B, Kund W (1988) Metabolites of 5-fluorouracil in plasma and urine, as monitored by19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res 48: 1680–1688

    Google Scholar 

  15. Kok RM, De Jong APJM, Van Groeningen CJ, Peters GJ, Lankelma J (1985) Highly sensitive determination of 5-fluorouracil in human plasma by capillary gas chromatography and negative ion chemical ionization mass spectrometry. J Chromatogr 343: 59–66

    Google Scholar 

  16. Liss RH, Chadwick M (1974) Correlation of 5-fluorouracil (NSC-19893) distribution in rodents with toxicity and chemotherapy in man. Cancer Chemother Rep 58: 777–786

    Google Scholar 

  17. Lönn U, Lönn S (1988) Increased levels of DNA lesions induced by leucovorin-5-fluoropyrimidine in human colon adenocarcinoma. Cancer Res 48: 4153–4157

    Google Scholar 

  18. Malet-Martino MC, Martino R (1989) The application of nuclear magnetic resonance spectroscopy to drug metabolism studies. Xenobiotica 19: 583–607

    Google Scholar 

  19. Marsh JC, Bertino JR, Katz KH (1991) The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 9: 371–380

    Google Scholar 

  20. McSheehy PMJ, Prior MJW, Griffiths JR (1989) Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo. Br J Cancer 60: 303–309

    Google Scholar 

  21. Moran RG, Scanlon KL (1991) Schedule dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 51: 4618–4623

    Google Scholar 

  22. Peters GJ, Van Groeningen CJ (1991) Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 2: 469–480

    Google Scholar 

  23. Peters GJ, Laurensse E, Leyva A, Pinedo HM (1986) Tissue homogenization using a microdismembrator for the measurement of enzyme activities. Clin Chim Acta 158:1983–1986

    Google Scholar 

  24. Peters GJ, Van Groeningen CJ, Laurensse E, Lankelma J, Leyva A, Pinedo HM (1987) Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. Cancer Chemother Pharmacol 20: 101–108

    Google Scholar 

  25. Peters GJ, Van Dijk J, Nadal J, Van Groeningen CJ, Lankelma J, Pinedo HM (1987) Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. In Vivo 1: 113–118

    Google Scholar 

  26. Peters GJ, Van Dijk J, Laurensse E, Van Groeningen CJ, Lankelma J, Leyva A, Nadal JC, Pinedo HM (1988) In vitro biochemical and in vivo biological studies of the uridine “rescue” of 5-fluorouracil. Br J Cancer 57: 259–265

    Google Scholar 

  27. Peters GJ, Van Groeningen CJ, Laurensse E, Pinedo HM (1991) A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 68:1903–1909

    Google Scholar 

  28. Peters GJ, Van Groeningen CJ, Van der Wilt CL, Smid K, Meijer S, Pinedo HM (1991) Effect of leucovorin on 5-fluorouracil induced inhibition of thymidylate synthase in patients with colorectal cancer. Adv Exp Med Biol 309A: 131–134

    Google Scholar 

  29. Pinedo HM, Peters GJ (1988) 5-Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653–1664

    Google Scholar 

  30. Port RE, Bachert P, Semmler W (1991) Kinetic modeling of in vivo nuclear magnetic resonance spectroscopy data: 5-fluorouracil in liver and liver tumors. Clin Pharmacol Ther 49: 497–505

    Google Scholar 

  31. Semmler W, Bachert-Baumann P, Gückel F, Ermark F, Schlag P, Lorenz WJ, Van Kaick G (1990) Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Radiology 174: 141–145

    Google Scholar 

  32. Shani J, Wolf W, Schlesinger T (1978) Distribution of [18F]-5-fluorouracil in tumor-bearing mice and rats. Int J Nucl Med Biol 5: 19–28

    Google Scholar 

  33. Smith, P, Mirabelli C, Fondacaro J, Ryan F, Dent J (1988) Intestinal 5-fluorouracil absorption: use of ussing chambers to assess transport and metabolism. Pharm Res 5: 598–603

    Google Scholar 

  34. Spoelstra EC, Pinedo HM, Dekker H, Peters GJ, Lankelma J (1991) Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system. Cancer Chemother Pharmacol 27: 320–325

    Google Scholar 

  35. Stevens AN, Morris PG, Iles RA, Sheldon PW, Griffiths JR (1984) 5-Fluorouracil metabolism monitored in vivo by19F NMR. Br J Cancer 50: 113–117

    Google Scholar 

  36. Van der Wilt CL, Pinedo HM, Smid K, Peters GJ (1992) Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon cancers. Cancer Res 52: 4922–4929

    Google Scholar 

  37. Van Groeningen CJ, Pinedo HM, Heddes J, Kok RM, De Jong APJM, Wattel E, Peters GJ, Lankelma J (1988) Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients during a dose escalation schedule. Cancer Res 48: 6956–6961

    Google Scholar 

  38. Visser GWM, Gorrée GCM, Peters GJ, Herscheid JDM (1990) On parameters that may influence the tissue distribution of 5-fluorouracil in mice. Cancer Chemother Pharmacol 26: 205–209

    Google Scholar 

  39. Wohlhueter RM, McIvor RS, Plagemann PGW (1980) Facilitated transport of uracil and 5-fluorouracil and permeation of orotic acid into cultured cells. J Cell Physiol 104: 309–319

    Google Scholar 

  40. Wolf W, Presant CA, Servis KL, El-Tahlawy A, Albright MJ, Barker PB, Ring, R III, Atkinson D, Ong R, King M, Singh M, Ray M, Wiseman C, Blaney D, Shani J (1990) Tumor trapping of 5-fluorouracil: in vivo19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc Natl Acad Sci USA 87: 492–496

    Google Scholar 

  41. Yamamoto S, Kawasaki T (1981) Active transport of 5-fluorouracil and its energy coupling in Ehrlich ascites tumor cells. J Biochem 90: 635–642

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peters, G.J., Lankelma, J., Kok, R.M. et al. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother. Pharmacol. 31, 269–276 (1993). https://doi.org/10.1007/BF00685670

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685670

Keywords

Navigation